Moderna up 6% premarket on pipeline update

|By:, SA News Editor

Recent IPO Moderna (NASDAQ:MRNA) is up 6% premarket on light volume following its update on several of its pipeline programs.


IND filed in U.S. for Phase 2 cohort of OX40L (mRNA-2416) in advanced ovarian cancer.

First patient dosed in Phase 1 study of OX40L + IL23 + IL36γ (mRNA-2752) in advanced/metastatic solid tumors or lymphoma.

Initiated planning for a Phase 2 study, with collaboration partner Merck (NYSE:MRK), evaluating personalized cancer vaccine candidate mRNA-4157

Rare Diseases:

IND submitted for Phase 1/2 study of mRNA-3704 in methylmalonic acidemia, an inherited disorder in which the body cannot break down certain proteins and fats.


Subscribe for full text news in your inbox